StreetInsider.com News Articles

China SXT Pharmaceuticals closes $12M registered direct offering

Fri, 09 Oct 2026 17:30:11 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a $12 million registered direct offering, with Univest Securities, LLC acting as sole placement agent, according to a press release.

Under the terms of the offering, the company sold 8,000,000 Class A ordinary shares at a purchase price of $1.50 per share to institutional investors, with the option to issue pre-funded warrants in lieu of shares.

The company also issued 8,000,000 warrants to the same investors at an exercise price of $1.50 per share. The warrants are immediately exercisable upon issuance and carry a one-year term. Each warrant includes a zero cash exercise option

Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 09 Oct 2026 17:30:00 -0400

New York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of $12 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an aggregate

Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 09 Oct 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an aggregate

Form 6-K China SXT Pharmaceutical For: Oct 09

Fri, 09 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261009/27172159.html

Form 424B5 China SXT Pharmaceutical

Fri, 09 Oct 2026 09:30:00 -0400

si-local-file:///var/storage/secattach/20261009/27169874.html

Form 6-K China SXT Pharmaceutical For: Oct 08

Thu, 08 Oct 2026 12:08:00 -0400

si-local-file:///var/storage/secattach/20261008/27165874.html

China SXT Pharmaceuticals plans $12M direct offering at $1.50 per share

Thu, 08 Oct 2026 09:23:19 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a registered direct offering of 8,000,000 Class A ordinary shares at $1.50 per share, with expected gross proceeds of approximately $12 million before placement agent fees and other expenses.

The Taizhou, China-based company also agreed to issue 8,000,000 warrants to the same institutional investors at an exercise price of $1.50 per share. The warrants are immediately exercisable upon issuance, carry a one-year term, and include a zero cash exercise option allowing holders to acquire up to nine Class A shares per warrant.

Investors will have an additional purchase right to acquire up to $12 million

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

Thu, 08 Oct 2026 09:22:00 -0400

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering.

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

Thu, 08 Oct 2026 09:22:00 -0400

Form 6-K China SXT Pharmaceutical For: Oct 08

Thu, 08 Oct 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20261008/27163724.html

Form EFFECT China SXT Pharmaceutical

Thu, 17 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260917/27072305.html

Form F-3/A China SXT Pharmaceutical

Fri, 28 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26998897.html

Form F-3/A China SXT Pharmaceutical

Fri, 28 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26998897.html

Form 6-K China SXT Pharmaceutical For: Aug 28

Fri, 28 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260828/26998866.html

Form 6-K China SXT Pharmaceutical For: Aug 28

Fri, 28 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260828/26998866.html

China SXT Pharmaceuticals announces 1-for-80 share consolidation

Wed, 05 Aug 2026 09:00:10 -0400

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026, according to a press release from the Taizhou, China-based company.

Prior to the consolidation, 105,704,077 Class A ordinary shares are issued and outstanding. Following the consolidation, approximately 1,321,301 Class A ordinary shares will be outstanding, with every 80 shares combined into one share. Fractional shares will be rounded up to the next whole share.

The company's Class A ordinary shares will continue trading on the Nasdaq Stock Market under the ticker symbol "SXTC" on a post-consolidation basis beginning

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Wed, 05 Aug 2026 09:00:00 -0400

TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par value per share, at a ratio of 1-for-80, effective on August 10, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on August 10, 2026. Upon the market opening on August 10, 2026, the Company’s Class A

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Wed, 05 Aug 2026 09:00:00 -0400

China SXT Pharmaceuticals closes $9M registered direct offering

Fri, 24 Jul 2026 17:30:08 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a registered direct offering raising $9 million in gross proceeds, according to a press release from placement agent Univest Securities, LLC.

The company sold 4,500,000 units to institutional investors at $2.00 per unit. Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share. The warrants are immediately exercisable upon issuance and expire one year from the issuance date.

Univest Securities, LLC served as the sole placement agent for the offering, which was made pursuant to a shelf registration statement on Form F-3 declared effective

China SXT Pharmaceuticals closes $9M registered direct offering

Fri, 24 Jul 2026 17:30:08 -0400

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a registered direct offering raising $9 million in gross proceeds, according to a press release from placement agent Univest Securities, LLC.

Univest Securities, LLC served as the sole placement agent for the offering, which was made pursuant to a shelf registration statement on Form F-3 declared effective

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

Fri, 24 Jul 2026 17:30:00 -0400

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an

Form 6-K China SXT Pharmaceutical For: Jul 24

Fri, 24 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260724/26813864.html